Hydrogen sulfide attenuates renal fibrosis by inducing TET‐dependent DNA demethylation on Klotho promoter. Issue 9 (30th July 2020)

• Record Type: Journal Article
• Authors: Gu, Yulu; Chen, Jing; Zhang, Han; Shen, Ziyan; Liu, Hong; Lv, Shiqi; Yu, Xixi; Zhang, Di; Ding, Xiaoqiang; Zhang, Xiaoyan
• Is Part Of: FASEB journal. Volume 34:Issue 9(2020)
• Page Start: 11474
• Page End: 11487
• Publication Date: 2020-07-30
• Subjects: CKD -- Fe2+ -- hypoxia -- ROS; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.201902957RR
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract: Hypoxia is a key pathogenetic characteristic of chronic kidney disease (CKD). Klotho has renoprotective effect and its expression is commonly suppressed in CKD patients. We showed that chronic hypoxia in unilateral ureteral obstruction model mice is associated with renal Klotho promoter methylation and expression silencing. Administration of low‐dose of sodium hydrosulfide (NaHS) effectively ameliorated renal tubulointerstitial fibrosis in the mouse model by demethylating Klotho promoter and restoring its expression. Mechanistically, hypoxia microenvironment in CKD reduced cellular oxygen availability and Fe 2+ concentration, and led to impaired activity of ten‐eleven translocation (TET), which is critical in maintaining Klotho promoter demethylation status. NaHS treatment greatly improved hypoxia condition, restored TET activity, reversed DNA methylation, and thus, increased Klotho expression. Our results strongly suggested that correcting hypoxia condition to restore TET activity could be a promising therapeutic strategy against CKD.